Abstract
Bendamustine followed by obinutuzumab and venetoclax provides clinical benefit without unexpected toxicity.
- ©2018 American Association for Cancer Research.
Log in using your username and password
Purchase Short Term Access
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
October 2018
Volume 8, Issue 10
Volume 8, Issue 10
Bendamustine, Obinutuzumab, and Venetoclax Achieve Responses in CLL
Jump to section
Advertisement